Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.80 |
| ▸ | MEN1 | O00255 | 4/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.80 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.80 |
| ▸ | GAA | P10253 | 3/20 | 0.80 |
| ▸ | HPGD | P15428 | 3/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.80 |
| ▸ | CASP1 | P29466 | 3/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.80 |
| ▸ | THRB | P10828 | 2/20 | 0.80 |
| ▸ | POLB | P06746 | 2/20 | 0.80 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.80 |
| ▸ | BLM | P54132 | 2/20 | 0.80 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.80 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.80 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.80 |
| ▸ | PLEC | Q15149 | 1/20 | 0.80 |
| ▸ | HTT | P42858 | 2/20 | 0.79 |
| ▸ | RAB9A | P51151 | 3/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10055032 | 1.00 | MAPT (0.80) | MAPTMEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL22783760 | 0.93 | MAPT (0.71) | MAPTMEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL22674849 | 0.91 | MAPT (0.69) | MAPTMEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL4592466 | 0.91 | MAPT (0.69) | MAPTMEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL6416118 | 0.89 | MEN1 (0.67) | MAPTMEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL19419957 | 0.89 | MEN1 (0.67) | MAPTMEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL171854 | 0.89 | MAPT (0.67) | MAPTMEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL11935858 | 0.89 | MAPT (0.67) | MAPTMEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL6414545 | 0.89 | MAPT (0.67) | MAPTMEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL14950714 | 0.89 | MAPT (1.00) | MAPTMEN1KMT2AL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115745808-B | Method for preparing secondary amine compound by catalyzing reduction of imine compound | 延安大学 | 2024-04-30 | — | — | CN | disclosed |
| CN-113861065-B | Method for preparing asymmetric imine or asymmetric secondary amine compound by photocatalysis | 苏州大学张家港工业技术研究院 | 2023-09-26 | — | — | CN | disclosed |
| US-11696937-B2 | Glycopeptide compounds having activity of resisting drug-resistant bacteria, and preparation method and application thereof | SHANGHAI LAIYI CENTER FOR BIOPHARMACEUTICAL R&D CO., LTD. (CN) | 2023-07-11 | — | — | US | disclosed |
| US-11696937-B2 | Glycopeptide compounds having activity of resisting drug-resistant bacteria, and preparation method and application thereof | SHANGHAI LAIYI CENTER FOR BIOPHARMACEUTICAL R&D CO., LTD. (CN) | 2023-07-11 | — | — | US | disclosed |
| CN-115745808-A | Method for preparing secondary amine compound by catalyzing reduction of imine compound | 延安大学 | 2023-03-07 | — | — | CN | disclosed |
| WO-2023003468-A1 | NOVEL INHIBITORS OF HISTONE DEACETYLASE (HDAC), AND METHODS, COMPOSITIONS AND USES RELATED THERETO. | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2023-01-26 | — | — | WO | disclosed |
| US-20210093691-A1 | Glycopeptide Compounds Having Activity Of Resisting Drug-Resistant Bacteria, And Preparation Method And Application Thereof | SHANGHAI LAIYI CENTER FOR BIOPHARMACEUTICAL R&D CO., LTD. (CN) | 2021-04-01 | — | — | US | disclosed |
| EP-3763728-A1 | GLYCOPEPTIDE COMPOUNDS HAVING ACTIVITY OF RESISTING DRUG-RESISTANT BACTERIA, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai LaiYi Center For Biopharmaceutical R&D Co., Ltd. (CN) | 2021-01-13 | — | — | EP | disclosed |
| US-20180079962-A1 | LIQUID CRYSTAL DISPLAY DEVICE AND MANUFACTURING METHOD THEREOF | MAGNOLIA PURPLE CORPORATION (JP) | 2018-03-22 | — | — | US | disclosed |
| US-9868907-B2 | Liquid crystal display device and manufacturing method thereof | JAPAN DISPLAY INC. (JP) | 2018-01-16 | — | — | US | disclosed |
| US-9028926-B2 | Liquid crystal display device and manufacturing method thereof | JAPAN DISPLAY INC. (JP) | 2015-05-12 | — | — | US | disclosed |
| US-20140046004-A1 | LIQUID CRYSTAL DISPLAY DEVICE AND MANUFACTURING METHOD THEREOF | JAPAN DISPLAY, INC. (JP) | 2014-02-13 | — | — | US | disclosed |
| EP-1994004-B9 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2013-04-17 | — | — | EP | disclosed |
| US-7960435-B2 | Anti-cancer agents and androgen inhibition activity compound | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960435-B2 | Anti-cancer agents and androgen inhibition activity compound | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100113600-A1 | ANTI-CANCER AGENTS AND ANDROGEN INHIBITION ACTIVITY COMPOUND | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113600-A1 | ANTI-CANCER AGENTS AND ANDROGEN INHIBITION ACTIVITY COMPOUND | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2010-05-06 | — | — | US | disclosed |
| US-20090053430-A1 | Liquid Crystal Display Device and Manufacturing Method Thereof | HITACHI DISPLAYS. LTD. | 2009-02-26 | — | — | US | disclosed |
| WO-2008076918-A9 | ANTI-CANCER AGENTS AND ANDROGEN INHIBITION ACTIVITY COMPOUND | UNIV MARYLAND (US) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008076918-A2 | ANTI-CANCER AGENTS AND ANDROGEN INHIBITION ACTIVITY COMPOUND | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210093691-A1 | Glycopeptide Compounds Having Activity Of Resisting Drug-Resistant Bacteria, And Preparation Method And Application Thereof | VIP, CUTA, MGAM | MAPT 3389/4885MEN1 3260/4885KMT2A 4167/4885 |
| US-11696937-B2 | Glycopeptide compounds having activity of resisting drug-resistant bacteria, and preparation method and application thereof | VIP, CUTA, MGAM | MAPT 3389/4885MEN1 3260/4885KMT2A 4167/4885 |
| US-20100113600-A1 | ANTI-CANCER AGENTS AND ANDROGEN INHIBITION ACTIVITY COMPOUND | AR, HTR3D, NR5A1 | MAPT 4558/4885MEN1 2290/4885KMT2A 1411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.